64O Lenvatinib plus pembrolizumab, pemetrexed, and a platinum (len + pembro + chemo) as first-line therapy for metastatic non squamous non-small cell lung cancer (NSCLC): Phase III LEAP-006 study
Year: 2023
Type: article
Study design: Clinical Trial
Abstract: LEAP-006 is a 2-part phase 3 study of len + pembro + chemo as first-line therapy for metastatic nonsquamous NSCLC (NCT03829319). Part 1 established len 8 mg/d as the recommended starting dose when added to pembro + chemo. We present results of part 2, a randomized, double-blind study of len + pembro + chemo vs placebo (pbo) + pembro + chemo.
Source: Immuno-Oncology Technology
Institutions: Yale Cancer Center, Yale University, Smilow Cancer Hospital, Yonsei University, Yonsei Cancer Hospital, Tongji University, Shanghai Pulmonary Hospital, Hospital Regional Universitario de Málaga, Ankara Yıldırım Beyazıt University, State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care, Centrum Onkologii, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Westmead Hospital, Centre Hospitalier Universitaire de Nantes, Soroka Medical Center, University Hospitals of Leicester NHS Trust, Eisai (United Kingdom), Merck & Co., Inc., Rahway, NJ, USA (United States), Hospital Universitario Insular de Gran Canaria
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,020
OpenAlex ID: W4389487537